AUGX vs. AMWL, NUTX, MPLN, VXRT, DBVT, AMLX, RNAC, DMAC, NOTV, and SYRS
Should you be buying Augmedix stock or one of its competitors? The main competitors of Augmedix include American Well (AMWL), Nutex Health (NUTX), MultiPlan (MPLN), Vaxart (VXRT), DBV Technologies (DBVT), Amylyx Pharmaceuticals (AMLX), Cartesian Therapeutics (RNAC), DiaMedica Therapeutics (DMAC), Inotiv (NOTV), and Syros Pharmaceuticals (SYRS). These companies are all part of the "medical" sector.
Augmedix (NASDAQ:AUGX) and American Well (NYSE:AMWL) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their community ranking, valuation, dividends, media sentiment, analyst recommendations, institutional ownership, earnings, risk and profitability.
In the previous week, Augmedix had 4 more articles in the media than American Well. MarketBeat recorded 6 mentions for Augmedix and 2 mentions for American Well. Augmedix's average media sentiment score of 0.93 beat American Well's score of 0.07 indicating that Augmedix is being referred to more favorably in the media.
Augmedix has a beta of 0.03, suggesting that its share price is 97% less volatile than the S&P 500. Comparatively, American Well has a beta of 1.12, suggesting that its share price is 12% more volatile than the S&P 500.
Augmedix currently has a consensus target price of $5.17, indicating a potential upside of 126.61%. American Well has a consensus target price of $1.00, indicating a potential upside of 100.56%. Given Augmedix's stronger consensus rating and higher possible upside, research analysts plainly believe Augmedix is more favorable than American Well.
American Well received 29 more outperform votes than Augmedix when rated by MarketBeat users. However, 60.00% of users gave Augmedix an outperform vote while only 47.76% of users gave American Well an outperform vote.
Augmedix has a net margin of -42.74% compared to American Well's net margin of -137.32%. American Well's return on equity of -46.76% beat Augmedix's return on equity.
Augmedix has higher earnings, but lower revenue than American Well. Augmedix is trading at a lower price-to-earnings ratio than American Well, indicating that it is currently the more affordable of the two stocks.
87.1% of Augmedix shares are held by institutional investors. Comparatively, 56.1% of American Well shares are held by institutional investors. 11.0% of Augmedix shares are held by insiders. Comparatively, 12.9% of American Well shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
Summary
Augmedix beats American Well on 11 of the 18 factors compared between the two stocks.
Get Augmedix News Delivered to You Automatically
Sign up to receive the latest news and ratings for AUGX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding AUGX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Augmedix Competitors List
Related Companies and Tools
